Reported 2 days ago
Viking Therapeutics, Inc. (NASDAQ:VKTX) is being seen favorably by analysts, with H.C. Wainwright reiterating a Buy rating and a target price of $102, citing the company's strong market position and effective therapies for metabolic disorders. Additionally, BTIG analyst Justin Zelin also maintains a Buy rating with a $125 target, emphasizing its advantages in the obesity and metabolic disease market.
Source: YAHOO